VERU INC. Liabilities Assumed
VERU INC. (VERU) reported Liabilities Assumed of $184.53 thousand for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:LiabilitiesAssumed1 · last filed 2026-08-10
- VERU INC. liabilities assumed for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- VERU INC. liabilities assumed for the quarter ending 2023-12-31 was $149.47K.
- VERU INC. liabilities assumed for fiscal 2017 was $8.16M.
| Period end | Liabilities Assumed 3 month | Liabilities Assumed 9 month | Liabilities Assumed 12 month |
|---|---|---|---|
| 2026-06-30 | $184.53K 10-Q · filed 2026-08-10 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-10 | ||
| 2024-12-31 | $0.00 10-Q · filed 2025-02-13 | ||
| 2023-12-31 | $149.47K 10-Q · filed 2025-02-13 | ||
| 2017-09-30 | $8.16M 10-K · filed 2018-01-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |